ArticleBritish journal of clinical pharmacology2026
Translation of a physiologically-based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post-partum women.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Translation of a physiologically-based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post-partum women.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non-pregnant, pregnant and post-partum women. To evaluate safety and efficacy of dabigatran etexilate in post-partum women using simulations and design a future clinical study to support model verification.
methodsAn integrated PBPK/PD model in healthy non-pregnant, pregnant and post-partum women was translated from the PBPK model in healthy men by capturing physiological changes. The model was also linked to established exposure-response relationships for coagulation indices and plasma-breast milk transfer using data from a pilot study. Finally, the model was used for simulation and the design of a prospective clinical study.
resultsThe model predicted comparable plasma concentration profiles between healthy men and healthy, pregnant and post-partum women, by capturing their physiological differences. The model also captured plasma concentration and activated partial thromboplastin time (a coagulation index) data from a pilot study in post-partum women available in the literature. A sample size of 20 and 50-60 were determined to be appropriate for safety and efficacy arms respectively, of a clinical trial for model verification.
conclusionAn integrated PBPK/PD model for dabigatran etexilate in post-partum women has been developed successfully. The model was used to design a future clinical trial examining safety and efficacy of dabigatran in postpartum women at risk of thromboembolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.